Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1036

1.

Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.

Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):727-31. doi: 10.1158/1055-9965.EPI-07-2570.

2.

No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.

Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):736-9. doi: 10.1158/1055-9965.EPI-07-2832.

3.

The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.

Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, McGuigan J, Comber H, Reynolds JV, Murray LJ.

Gastroenterology. 2009 Mar;136(3):799-805. doi: 10.1053/j.gastro.2008.12.005. Epub 2008 Dec 3.

PMID:
19162028
4.
5.

Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.

Mulholland HG, Cantwell MM, Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, McGuigan J, Reynolds JV, Comber H, Murray LJ.

Cancer Causes Control. 2009 Apr;20(3):279-88. doi: 10.1007/s10552-008-9242-6. Epub 2008 Oct 7.

PMID:
18839322
6.

Risk factors, DNA damage, and disease progression in Barrett's esophagus.

Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, Wild CP.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5.

7.

Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.

Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y.

J Clin Gastroenterol. 2011 Sep;45(8):665-72. doi: 10.1097/MCG.0b013e318207f240.

PMID:
21325951
8.

Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL, Casson AG.

Mol Carcinog. 2008 Apr;47(4):275-85.

PMID:
17849424
9.

COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma.

Moons LM, Kuipers EJ, Rygiel AM, Groothuismink AZ, Geldof H, Bode WA, Krishnadath KK, Bergman JJ, van Vliet AH, Siersema PD, Kusters JG.

Am J Gastroenterol. 2007 Nov;102(11):2373-9. Epub 2007 Jun 20.

PMID:
17581270
10.

Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.

Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ.

Cancer Res. 2006 May 1;66(9):4975-82.

11.

Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Kala Z, Dolina J, Marek F, Izakovicova Holla L.

J Hum Genet. 2007;52(6):527-34. Epub 2007 May 3.

PMID:
17476458
12.

Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.

O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV.

Am J Gastroenterol. 2005 Jun;100(6):1257-64.

PMID:
15929754
13.

Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?

Gough MD, Ackroyd R, Majeed AW, Bird NC.

Am J Gastroenterol. 2005 May;100(5):1012-8.

PMID:
15842572
14.

Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.

De Gottardi A, Dumonceau JM, Bruttin F, Vonlaufen A, Morard I, Spahr L, Rubbia-Brandt L, Frossard JL, Dinjens WN, Rabinovitch PS, Hadengue A.

Mol Cancer. 2006 Oct 20;5:48.

15.

Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma.

van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH.

Cancer Res. 1999 Feb 1;59(3):586-9.

16.

Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.

Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T.

J Physiol Pharmacol. 2010 Aug;61(4):409-18.

17.

A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma.

Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, Johnston BT, Comber H, McGuigan J, Reynolds JV, Murray LJ.

Carcinogenesis. 2007 Jun;28(6):1323-8. Epub 2007 Feb 2.

PMID:
17277236
18.

Barrett's esophagus and medications that relax the lower esophageal sphincter.

Corley DA, Levin TR, Habel LA, Buffler PA.

Am J Gastroenterol. 2006 May;101(5):937-44.

PMID:
16573773
19.
20.

The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.

Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM.

Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7.

Supplemental Content

Support Center